title: How can we optimize treatment of HER2-positive metastatic breast cancer?
authors.affiliation: Duke University Medical Center, Durham, North Carolina, USA.
authors.forename: Erika P
authors.initials: EP
authors.lastname: Hamilton
authors.forename: Kimberly L
authors.initials: KL
authors.lastname: Blackwell
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases